A Tariff Cannot Deliver a Factory

Pandora opened a $150 million jewellery factory in Ho Chi Minh City on October 1, adding its first production site outside Thailand. The investment gives supply-chain resilience a concrete address—and puts it in Vietnam. The plant will serve the company’s global business rather than particular export markets, even as its chief executive faces questions about potentially higher U.S. tariffs on Vietnamese goods. This is diversification with a factory attached, not a promise that resilience must carry an American return address. RTÉ

The timetable matters as much as the cheque. Chief executive Berta de Pablos-Barbier says Vietnam will initially represent roughly 15% of Pandora’s global capacity, reaching one-third at full capacity by 2030. The facility is expected to increase overall manufacturing capacity by around 50% and eventually employ 7,000 people. Those are expected capabilities and jobs, not the opening-day payroll. Even a funded project with an unveiled first piece of jewellery still has a production ramp ahead of it. RTÉ

Pandora’s explanation for choosing Vietnam includes its skilled workforce, jewellery-making tradition, infrastructure and business environment. Those are the operating ingredients behind the investment. The company’s response to trade uncertainty is to build around them over a decade; the reporting does not establish that tariffs caused the project. That makes the factory a useful benchmark for evaluating manufacturing promises: specify the location, resources and timetable. A tariff announcement can change the arithmetic. It does not arrive with 7,000 trained workers in the envelope. RTÉ

The pharmaceutical tariff structure described by Axios exposes a different starting position. Its account identifies 100% duties on certain patented drugs and ingredients, with smaller companies particularly vulnerable because they depend on overseas manufacturing. Some own no production facilities at all and contract with manufacturers in places such as India or Singapore. Brookings economist Marta Wosińska identifies more than 100 firms with products subject to duties that may lack the resources to move production to the United States. For these businesses, pressure to relocate is also a demand to find an affordable way to manufacture. Axios

There are alternatives to building a company-owned factory. Axios describes domestic contract manufacturing as a possible route, since new facilities and workforces could be prohibitively expensive. It also reports three-year tariff exemptions for companies entering voluntary most-favored-nation pricing agreements and committing to onshoring; an onshoring commitment alone carries a reported 20% tariff until 2030. These choices make adjustment depend on manufacturing arrangements and exemption terms together. Pandora’s funded expansion illustrates one path; a smaller biotech might need access to someone else’s production capacity. The contrast concerns resources, not identical tariff exposure. Axios RTÉ

The possible responses also extend beyond investment. Industry observers cited by Axios describe selling a product, merging with a larger drugmaker or reducing operations; manufacturers could pass costs to purchasers through higher list prices or lower rebates. None is an established outcome in this account. But each identifies a different destination for the pressure: ownership, operations or purchasing terms. Consumers should therefore resist translating a duty percentage directly into a predicted medicine-price increase. Business readers should be equally wary of translating it directly into a new factory. The intervening decision is the story. Axios

The government’s separate forced-labor tariff policy contains its own recognition that replacing imports has practical limits. USTR’s explanation assigns a 10% duty to investigated economies meeting specified criteria for forced-labor import prohibitions or commitments, and 12.5% to the others. These are rates tied to governments’ policies and commitments. They should not be read as a finding that every affected shipment was made with forced labor. The policy’s stated target is the failure to impose and effectively enforce import prohibitions. USTR

Its product-exemption criteria are revealing. USTR identifies raw materials whose taxation could leave domestic supply unavailable, products whose taxation could cause economy-wide disruption, and goods that cannot be produced in sufficient quantities or at reasonable prices in the United States—or obtained elsewhere. The policy thus explicitly allows for circumstances in which an import duty encounters an inadequate replacement supply. The tariff schedule has room for the factory that does not exist, or cannot produce enough at a reasonable cost. Recognizing those circumstances, however, does not itself supply the missing capacity. USTR

That is the useful connection to pharmaceuticals, despite the different regimes: available production alternatives help determine how pressure can be answered. Pharmaceutical exemptions also matter, including specified specialty-drug categories and possible public-health carve-outs. Axios reports uncertainty about decision timing and refunds for duties paid during review. An exemption route can therefore change exposure without immediately settling a firm’s costs. Neither USTR’s criteria nor the pharmaceutical options establish that every potentially eligible product has received relief. For a buyer or business, the operative question is the applicable treatment and feasible supply alternative, not the largest percentage in the announcement. Axios USTR

G20 trade ministers left their October 1 meeting in Milwaukee without an agreement to curb excess capacity, and without a deal on forced labor. The Trump administration argues that overproduction in industries including steel, autos, batteries and semiconductors depresses prices and undermines American manufacturers. Trade Representative Jamieson Greer described the talks as constructive, but agreement on a response remained out of reach. Naming a problem, it turns out, does not reserve everyone a seat on the same policy bus. AP

The forced-labor impasse matters because USTR’s tariff rationale asks other governments to change their import-prohibition policies. Its account describes unilateral duties on 60 economies; the Milwaukee meeting produced no common agreement on that issue. This leaves coordination unresolved while the United States pursues pressure through its own tariff regime. It does not tell us whether those duties have succeeded or failed economically. It does show why a tariff rate cannot stand in for evidence that the requested policy change has occurred. USTR AP

The equivalent test for a manufacturing promise is concrete: which producer can supply the replacement, when can it operate, and which exemption applies in the meantime? The pharmaceutical account supplies possible paths through domestic contracting, ownership changes and purchaser costs; Pandora supplies an actual investment with a ramp toward 2030. These cases leave room for adaptation, but demand specificity about its form. For consumers, a possible list-price or rebate response remains a possibility until it happens. For business readers, an investment forecast needs something as tangible as Pandora’s site and calendar. Customs can collect a duty without delivering the industrial result attached to the speech. Axios RTÉ